Your browser doesn't support javascript.
Cardiovascular Toxicities of Androgen Deprivation Therapy.
Challa, Azariyas A; Calaway, Adam Christopher; Cullen, Jennifer; Garcia, Jorge; Desai, Nihar; Weintraub, Neal L; Deswal, Anita; Kutty, Shelby; Vallakati, Ajay; Addison, Daniel; Baliga, Ragavendra; Campbell, Courtney M; Guha, Avirup.
  • Challa AA; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Calaway AC; Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Cullen J; Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Cleveland, OH, USA.
  • Garcia J; Division of Solid Tumor Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
  • Desai N; Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.
  • Weintraub NL; Center for Outcomes Research and Evaluation, New Haven, CT, USA.
  • Deswal A; Vascular Biology Center, Augusta University, August, GA, USA.
  • Kutty S; Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA.
  • Vallakati A; Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Addison D; The Helen B. Taussig Heart Center, The Johns Hopkins Hospital and Johns Hopkins University, Baltimore, MD, USA.
  • Baliga R; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Campbell CM; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Guha A; Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Curr Treat Options Oncol ; 22(6): 47, 2021 04 17.
Article in English | MEDLINE | ID: covidwho-1188176
ABSTRACT
OPINION STATEMENT Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events. Emerging data supports decreased cardiovascular risk of gonadotropin releasing hormone (GnRH) antagonists compared to agonists. Ongoing clinical trials are assessing the relative safety of different modalities of androgen deprivation therapy. Racial disparities in cardiovascular outcomes in prostate cancer patients are starting to be explored. An intriguing inquiry connects androgen deprivation therapy with reduced risk of COVID-19 infection susceptibility and severity. Recognition of the cardiotoxicity of androgen deprivation therapy and aggressive risk factor modification are crucial for optimal patient care.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / Cardiovascular Diseases / Antineoplastic Agents, Hormonal Type of study: Observational study / Prognostic study Limits: Humans / Male Language: English Journal: Curr Treat Options Oncol Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: S11864-021-00846-z

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / Cardiovascular Diseases / Antineoplastic Agents, Hormonal Type of study: Observational study / Prognostic study Limits: Humans / Male Language: English Journal: Curr Treat Options Oncol Journal subject: Neoplasms Year: 2021 Document Type: Article Affiliation country: S11864-021-00846-z